• Consider a cautious or underweight stance on Moderna (MRNA) near the cited $234–$235 price: the speaker’s rough model suggested its cancer-vaccine opportunity would need about $25 billion in revenue to support that valuation, and the vaccine is not yet approved.
• Watch upcoming ESMO data and the treatment’s regulatory and commercial progress before reassessing MRNA; the bullish case depends on unusually large sales, with some economics shared with Merck (MRK).
• The speaker was bearish on CoreWeave (CRWV) and data-center stocks, citing debt and weak share performance, but provided no price targets or detailed analysis.

Moderna (MRNA)

• The speaker described Moderna as trading around $234–$235 per share, with roughly 400 million shares and a market value near $94 billion.
• He estimated the company had about $7 billion in cash and $2 billion in property, plant, and equipment. After accounting for debt, he put enterprise value at roughly $85 billion.
• The speaker said Moderna is spending heavily on R&D and that its valuation depends largely on future products, particularly its cancer vaccine. He also noted that its RSV vaccine, mRESVIA, had generated only about $3 million in revenue in the quarter discussed.
• The cancer-vaccine case centers on intismeran autogene (mRNA-4157/V940), developed with Merck, in combination with Keytruda for resected melanoma. A company announcement reported statistically significant and clinically meaningful improvements in recurrence-free and distant metastasis-free survival versus Keytruda alone. The speaker expected further data at ESMO.
• The speaker’s rough market model used an estimated 100,000 potential U.S. patients and a hypothetical $100,000 price, producing $10 billion in revenue. He cautioned that this was only a rough estimate and that the treatment was not yet approved.
• In his valuation scenarios, $10 billion in revenue still supported a value of about $100 per share, below the price discussed. He estimated that around $25 billion in revenue would be needed to support the then-current share price; $30 billion was only marginally attractive in his model, while $35 billion could imply roughly 50% upside.
• He emphasized that reaching $35 billion would require an extraordinary commercial outcome—potentially making the cancer vaccine larger than Keytruda—and said expansion into other tumor types was speculative. He also modeled substantial costs, including a significant share going to Merck.
• The speaker was skeptical that Moderna’s other products would materially support the valuation soon, and said the company’s COVID-related products and mRESVIA were not selling strongly in the discussion.

Takeaways

• The transcript presents a bearish valuation view at the share price discussed: the speaker’s base scenario for the cancer vaccine did not justify the market valuation.
• The bull case depends on successful clinical development, regulatory approval, and sales at a scale far beyond the speaker’s $10 billion scenario. The transcript does not establish that outcome as likely.
• Investors assessing the thesis could focus on the upcoming melanoma data, the treatment’s path to approval, its eventual commercial reach, and how much revenue and profit would be shared with Merck. The patient count and pricing used in the speaker’s model were rough assumptions, not confirmed market estimates.

Merck (MRK)

• Merck is Moderna’s partner on intismeran autogene, used with Merck’s cancer drug Keytruda in the melanoma study.
• The speaker included Merck’s share of the economics in his Moderna model and estimated that a substantial portion of the treatment’s costs or proceeds would go to Merck.
• Comparing the two companies, he asked whether Merck might be the better long investment if the Moderna cancer-vaccine opportunity required very high sales assumptions.

Takeaways

• The transcript frames Merck as a way to participate in the cancer-treatment opportunity, while highlighting that Moderna would not capture all of the economics.
• The speaker did not provide a Merck price target or a full valuation analysis, so the comparison is a prompt for further research rather than a specific recommendation.

Keytruda

• Keytruda is the established drug used as the comparison treatment in the melanoma study with intismeran autogene.
• The speaker cited projected Keytruda sales of about $33 billion for the year discussed and argued that Moderna’s cancer vaccine would need to reach an exceptional scale to support the higher revenue scenarios in his model.
• He said Keytruda faces biosimilar competition and that efforts to extend its product life may be difficult.

Takeaways

• Keytruda serves as a scale benchmark for the Moderna bull case: the speaker’s $35 billion Moderna scenario would put the cancer vaccine above the sales level he cited for Keytruda.
• The transcript’s comments on biosimilars and product extensions are relevant to Keytruda’s outlook, but no specific timeline or price target was given.

CoreWeave (CRWV)

• The speaker joked about the company’s debt, calling it “Debtweave,” and said it had enough debt to be notable.
• He said CoreWeave could barely sustain a rally and described data-center stocks broadly as unattractive, calling them potential shorts.

Takeaways

• The speaker’s sentiment toward CoreWeave and the broader data-center group was bearish, with debt and weak share performance cited as concerns.
• The transcript provides no valuation, price target, or detailed company-specific analysis, so it offers only a high-level negative view.

“Iron” / Possible IREN

• The speaker referred to a company as “Iron” and said it was probably a short, grouping it with data-center stocks. The transcript does not clearly establish the company’s identity; it may refer to IREN, but that identification is uncertain.

Takeaways

• The only clear signal is the speaker’s bearish view of data-center stocks. Confirm the company’s identity before drawing any investment conclusion.

Silence Therapeutics (SLN)

• SLN was mentioned briefly while the speaker looked for a prior post about it. No company analysis, valuation, or investment view was provided.

Takeaways

• The transcript does not contain enough information to form an investment thesis on SLN.

Celast Life Sciences

• A listener suggested looking at Celast Life Sciences, and the speaker replied that they had already checked it out. No further details or opinion were provided.

Takeaways

• The mention provides no actionable investment information or clear investment view.